FCCC LOGO Faculty Publications
Lara H , Wang Y , Beltran AS , Juarez-Moreno K , Yuan X , Kato S , Leisewitz AV , Cuello Fredes M , Licea AF , Connolly DC , Huang L , Blancafort P
Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors
J Biol Chem. 2012 Aug 24;287(35) :29873-86
PMID: 22782891    PMCID: PMC3436144    URL: https://www.ncbi.nlm.nih.gov/pubmed/22782891
Back to previous list
Abstract
Ovarian cancer is the leading cause of death among gynecological malignancies. It is detected at late stages when the disease is spread through the abdominal cavity in a condition known as peritoneal carcinomatosis. Thus, there is an urgent need to develop novel therapeutic interventions to target advanced stages of ovarian cancer. Mammary serine protease inhibitor (Maspin) represents an important metastasis suppressor initially identified in breast cancer. Herein we have generated a sequence-specific zinc finger artificial transcription factor (ATF) to up-regulate the Maspin promoter in aggressive ovarian cancer cell lines and to interrogate the therapeutic potential of Maspin in ovarian cancer. We found that although Maspin was expressed in some primary ovarian tumors, the promoter was epigenetically silenced in cell lines derived from ascites. Transduction of the ATF in MOVCAR 5009 cells derived from ascitic cultures of a TgMISIIR-TAg mouse model of ovarian cancer resulted in tumor cell growth inhibition, impaired cell invasion, and severe disruption of actin cytoskeleton. Systemic delivery of lipid-protamine-RNA nanoparticles encapsulating a chemically modified ATF mRNA resulted in inhibition of ovarian cancer cell growth in nude mice accompanied with Maspin re-expression in the treated tumors. Gene expression microarrays of ATF-transduced cells revealed an exceptional specificity for the Maspin promoter. These analyses identified novel targets co-regulated with Maspin in human short-term cultures derived from ascites, such as TSPAN12, that could mediate the anti-metastatic phenotype of the ATF. Our work outlined the first targeted, non-viral delivery of ATFs into tumors with potential clinical applications for metastatic ovarian cancers.
Notes
Lara, Haydee Wang, Yuhua Beltran, Adriana S Juarez-Moreno, Karla Yuan, Xinni Kato, Sumie Leisewitz, Andrea V Cuello Fredes, Mauricio Licea, Alexei F Connolly, Denise C Huang, Leaf Blancafort, Pilar eng CA136596/CA/NCI NIH HHS/ R01 CA170370/CA/NCI NIH HHS/ CA083638/CA/NCI NIH HHS/ CA129835/CA/NCI NIH HHS/ CA006927/CA/NCI NIH HHS/ 1R01CA125273/CA/NCI NIH HHS/ R01 CA136596/CA/NCI NIH HHS/ R01 CA125273/CA/NCI NIH HHS/ P50 CA083638/CA/NCI NIH HHS/ 3R01CA125273-03S1/CA/NCI NIH HHS/ R01 CA129835/CA/NCI NIH HHS/ P30 CA006927/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. J Biol Chem. 2012 Aug 24;287(35):29873-86. doi: 10.1074/jbc.M112.360768. Epub 2012 Jul 10.